Skip to main content

Novartis medication effective against psoriasis

| News

Novartis medication effective against psoriasis

30.11.2017

The Basel-based pharmaceutical company Novartis has released positive data on the long-term efficacy of its medication Cosentyx, which is used for hard-to-treat types of psoriasis.

Novartis in Basel. (Img: lucarista/shutterstock)

Novartis announced first-of-its-kind long-term data showing that Cosentyx is effective in treating nail and palmoplantar psoriasis. Up to 90 per cent of psoriasis patients may develop these types of psoriasis, which affect the palms of the hands and the soles of the feet. These hard-to-treat types of psoriasis seriously impact a patient’s quality of life by reducing mobility.

Two clinical studies have now shown that Cosentyx provides sustained improvements for up to 2.5 years. In the TRANSFIGURE study, patients with nail psoriasis who were treated with Cosentyx experienced an improvement of 63 per cent and 73 per cent, depending on the dose taken. In the GESTURE study, 53 per cent and 59 per cent of patients with palmoplantar psoriasis achieved clear or almost clear palms and soles at 2.5 years.

Cosentyx inhibits the protein interleukin 17A (IL-17A), which is involved in the development and progression of psoriasis.

“As an IL-17A inhibitor, Cosentyx provides a highly targeted treatment option that can not only effectively treat the plaques caused by psoriasis, as evident by recently presented 5-year data, but also hard-to-treat forms and associated arthritic conditions,” said Eric Hughes, Global Development Unit Head, Immunology & Dermatology.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.